[go: up one dir, main page]

MA54388A - Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6 - Google Patents

Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6

Info

Publication number
MA54388A
MA54388A MA054388A MA54388A MA54388A MA 54388 A MA54388 A MA 54388A MA 054388 A MA054388 A MA 054388A MA 54388 A MA54388 A MA 54388A MA 54388 A MA54388 A MA 54388A
Authority
MA
Morocco
Prior art keywords
cdk4
inhibitors
methods
treating cancer
cancer resistant
Prior art date
Application number
MA054388A
Other languages
English (en)
Inventor
Heike Arlt
Teeru Bihani
Hitisha Patel
Nianjun Tao
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of MA54388A publication Critical patent/MA54388A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA054388A 2018-12-06 2019-12-06 Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6 MA54388A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862776323P 2018-12-06 2018-12-06

Publications (1)

Publication Number Publication Date
MA54388A true MA54388A (fr) 2021-10-13

Family

ID=69063871

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054388A MA54388A (fr) 2018-12-06 2019-12-06 Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6

Country Status (17)

Country Link
US (2) US20210330612A1 (fr)
EP (1) EP3890834A1 (fr)
JP (1) JP7504097B2 (fr)
KR (1) KR20210100137A (fr)
CN (2) CN113164779A (fr)
AU (1) AU2019395093B2 (fr)
BR (1) BR112021010110A2 (fr)
CA (1) CA3121930A1 (fr)
EA (1) EA202191283A1 (fr)
IL (1) IL283659A (fr)
JO (1) JOP20210137A1 (fr)
MA (1) MA54388A (fr)
MX (1) MX2021006411A (fr)
PH (1) PH12021551319A1 (fr)
SG (1) SG11202105531XA (fr)
UA (1) UA130036C2 (fr)
WO (1) WO2020118213A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3689868T3 (pl) 2016-12-01 2024-03-11 Arvinas Operations, Inc. Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
TW202237117A (zh) * 2020-12-14 2022-10-01 美商亞文納營運公司 使用四氫萘衍生物作為雌激素受體降解劑治療乳癌之方法
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN116327894A (zh) * 2023-04-10 2023-06-27 上海市第一妇婴保健院 一种治疗kras突变的卵巢癌的组合药物及其应用
WO2025202871A1 (fr) * 2024-03-27 2025-10-02 Pfizer Inc. Procédés d'identification de biomarqueurs de réponse à un traitement et leur utilisation avec un inhibiteur de cdk4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
MX393599B (es) 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
CN117417263A (zh) * 2017-01-05 2024-01-19 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
CN112423844B (zh) * 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式

Also Published As

Publication number Publication date
JP7504097B2 (ja) 2024-06-21
WO2020118213A1 (fr) 2020-06-11
IL283659A (en) 2021-07-29
KR20210100137A (ko) 2021-08-13
US20250319044A1 (en) 2025-10-16
CN113164779A (zh) 2021-07-23
JOP20210137A1 (ar) 2023-01-30
EA202191283A1 (ru) 2021-10-13
AU2019395093B2 (en) 2025-01-23
SG11202105531XA (en) 2021-06-29
JP2022511498A (ja) 2022-01-31
UA130036C2 (uk) 2025-10-22
BR112021010110A2 (pt) 2021-08-24
CN119548484A (zh) 2025-03-04
AU2019395093A1 (en) 2021-06-24
PH12021551319A1 (en) 2022-05-16
MX2021006411A (es) 2021-07-21
CA3121930A1 (fr) 2020-06-11
US20210330612A1 (en) 2021-10-28
EP3890834A1 (fr) 2021-10-13

Similar Documents

Publication Publication Date Title
MA54388A (fr) Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6
EP3423488A4 (fr) Méthodes de traitement du cancer
MA46954A (fr) Méthodes de traitement d'états inflammatoires
EP3426271A4 (fr) Méthodes de traitement de tumeurs solides ou lymphatiques par polythérapie
EP3288383A4 (fr) Méthodes de traitement du cancer
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
EP3983445A4 (fr) Compositions et méthodes de traitement du cancer
EP3405203A4 (fr) Méthodes de traitement du cancer
EP3440112A4 (fr) Méthodes de traitement du cancer
EP3341080A4 (fr) Méthode de traitement du cancer
EP3389634A4 (fr) Méthodes de traitement du cancer
EP3589659A4 (fr) Composés et méthodes de traitement du cancer
EP3522934A4 (fr) Compositions et méthode pour le traitement de la rénopathie
EP3937964A4 (fr) Traitement de cancers induits par des oncogènes
EP3820461A4 (fr) Méthode de traitement du cancer
MA46361A (fr) Traitement du cancer de la prostate
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3389652A4 (fr) Méthodes de traitement du cancer
EP3787625A4 (fr) Méthodes de traitement du cancer
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3298141A4 (fr) Compositions et méthodes de traitement du cancer
EP3328372A4 (fr) Compositions et méthodes de traitement du cancer
EP3852816A4 (fr) Méthodes de traitement de cancer